Based on the progress in the diagnosis and management of gliomas from 2016, the term IDH-mutant GBM is discontinued and replaced with IDH-mutant astrocytoma, WHO grade 4 (Figure 1, Supplementary Table S1) [37]. The gene discussed is IDH1; the disease is central nervous system cancer.